ccRCC tumors have a high frequency of CD8+ and CD4+ T cells in the tumor microenvironment (TME), making them a favorable candidate for immune checkpoint blockade therapy (ICB) (7, 8). The gene discussed is CD8A; the disease is neoplasm.